Search results
2 new COVID variants called 'FLiRT' are spreading in the U.S. What are the symptoms?
TODAY via Yahoo News· 1 day agoThe new "FLiRT" COVID-19 variants, including KP.2, are spreading in the United States. Will there be...
CDC says bird flu viruses "pose pandemic potential," cites major knowledge gaps
WINK TV Southwest Florida· 9 hours agoBird flu continues to appear to pose a “low risk to the general public” for now, the Centers for...
...-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on...
KFDX Wichita Falls· 2 days agoTarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 2 days agoRevenue: Grew 7% year-over-year to $3.1 billion, excluding COVID antibodies contributions. Net Income: First quarter diluted net income per share was $9.55. Free Cash Flow: Generated $1.< ...
Realising the potential of correlates of protection for vaccine development, licensure and use:...
Nature· 6 days agoVaccine development, particularly late-stage development is costly, time-consuming and is associated with high risk of candidate failure, with as few as 10% of vaccine candidates achieving licensure ...
... III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for...
WKBN 27 Youngstown· 2 days agoHanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study ...
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
FOX21 Colorado Springs· 5 days agoDelivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected ...
OraSure Technologies (NASDAQ:OSUR) Upgraded to Buy by StockNews.com
ETF DAILY NEWS· 3 days agoStockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Separately, Evercore ISI cut their price ...
FDA Issues Final Rule on Laboratory-Developed Tests | JD Supra
JD Supra· 3 days agoOn April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs). The rule explicitly categorizes in vitro...
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Zacks· 3 days agoFree Report) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This quarterly report represents an earnings surprise of 15.38%. A quarter ...
